ДФДарья Андреевна Фисенко

Дарья Андреевна Фисенко

*This is an algorithmically generated author record based on publicly available information.

Дарья Андреевна Фисенко has a total of 45 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Results of a Two-Year Comprehensive Follow-Up of Patients with Spinal Muscular Atrophy Type I Who Received Gene Therapy with Onasemnogen Abeparvovek

    by A. L. Kurenkov, L. M. Kuzenkova, E. V. Uvakina, V. V. Chernikov, S. G. Popovich, D. A. Fisenko, B. I. Bursagova, O. V. Globa, N. V. Andreenko, L. M. Abdullaeva, et al.

    Introduction . Spinal muscular atrophy (SMA) is among the most severe inherited neuromuscular diseases. The development of pathogenetic treatment methods, including gene therapy, and their widespread clinical adoption has ushered in a new era in SMA treatment, making it possible not only to halt the progression of the disease but also to improve patients’ functional capabilities. Aim : to evaluate the efficacy of gene therapy in a real-world clinical practice with a 2-year follow-up study of patients with SMA type I who received treatment with onasemnogene abeparvovec. Materials and methods . The study included 73 patients with SMA type I. The disease was confirmed by molecular genetic testing.The diagnosis of SMA type I in 22 patients (30.1%) was established due to the development of the clinical picture of the disease and after confirmatory DNA diagnostics. In 51 patients (69.9%), initially identified as part of expanded neonatal screening, the diagnosis was established immediately after the onset of the first SMA symptoms. The mean age at the time of gene therapy was 2.78±1.87 months (95% CI 2.35–3.22), min 1.00, max 7.00. A comprehensive assessment of treatment effectiveness included clinical (the main the motor development milestones according to WHO, HINE-2 and CHOP-INTEND scores) and electroneuromyographic (latency, amplitude and area of the negative peak of the distal compound muscle action potential during electrical stimulation of the ulnar nerve at the wrist, the motor nerve conduction velocity of the ulnar nerve on the forearm) parameters before the initiation of gene therapy and 6, 12, 18 and 24 months after its implementation. Results . Following gene therapy, a large number of patients with SMA type I were able to achieve basic motor skills: 42.5% had good head control in the prone position; 78.1% rolled over from a supine to prone position; 47.2% sitting without support; 31.9% standing with assistance; 23.2% hands-&-knees crawling; 20.0% walking with assistance; 13.2% standing alone; 5.7% walking alone. However, most patients reached motor development milestones later than the WHO standards. By the end of the observation period, the HINE-2 score in patients with SMA type I significantly increased and amounted to Me 18.50 (16.00–24.00) points, with three children achieving the maximum score. The CHOP-INTEND scale score also increased significantly and amounted to Me 60.00 (58.00–64.00) points by the end of the 2-year observation period, with 17 children (23.3%) achieving the maximum score. Before gene therapy, patients with type I SMA had low values of the amplitude [Me 0.32 mV (0.15–0.81)] and area [Me 0.80 ms×mV (0.36–1.70)] of the compound muscle action potential. 24 months after gene therapy, the values of the amplitude and area significantly increased [Me 0.80 mV (0.60–1.20) and Me 1.40 ms×mV (1.00–2.10), respectively]. However, they did not reach the electroneuromyographic values of children without neurological pathology. During clinical and electroneuromyographic assessment in the dynamics of 2-year follow-up, it was not possible to establish statistically significant differences in patients with SMA type I depending on the onset of expanded neonatal screening. Conclusion . Gene therapy in patients with SMA type I results in significant improvements in motor development. Despite persistent delays in motor skill development, a large number of patients achieved key milestones in early motor development, as demonstrated by significant increases in HINE-2 and CHOP-INTEND scores and improved electroneuromyographic parameters.

  • Open Access

    Results of a two-year comprehensive follow-up in patients with spinal muscular atrophy who received gene therapy with onasemnogen abeparvovec at the presymptomatic stage of the disease

    by Людмила Михайловна Кузенкова, Алексей Львович Куренков, Евгения Владимировна Увакина, Дарья Андреевна Фисенко, Владислав Владимирович Черников, Елена Леонидовна Семикина, София Георгиевна Попович, Бэлла Ибрагимовна Бурсагова, Оксана Валерьевна Глоба, Наталья Владимировна Андреенко, et al.

    Introduction. The use of gene therapy in patients with spinal muscular atrophy (SMA) has led to a significant improvement in the prognosis of motor development. The inclusion of SMA in the expanded neonatal screening in the Russian Federation allowed not only identifying patients as early as possible, but also gene therapy at the presymptomatic stage of the disease became available for some of them.Objective. To evaluate the effectiveness of gene therapy in real clinical practice during 2 years of follow-up of SMA patients treated with onasemnogen abeparvovec at the presymptomatic stage of the disease.Materials and methods. The study included thirty five SMA children, with a genetically verified diagnosis of SMA without developing symptoms of the disease. The diagnosis of SMA was established during the pilot project of the extended neonatal screening or from 01/01/2023 as part of the extended neonatal screening. The diagnosis was verified during DNA diagnostics. Deletion of exons 7 and/or 8 of the SMN1 gene in the homozygous state was detected in all children. All patients received gene therapy with onasemnogen abeparvovec, the average age at the time of therapy was 2.00 ± 0.94 months (95% CI 1.68–2.32), min — 1.00, max — 5.00. A comprehensive assessment was conducted of clinical (the motor development milestones according to WHO, HINE-2 and CHOP-INTEND scores), electroneuromyographic (latency, amplitude and area of the negative peak of the compound muscle action potential during electrical stimulation of the ulnar nerve on the wrist; the motor nerve conduction velocity of the ulnar nerve on the forearm) and biochemical parameters (levels of light and heavy chains of neurofilaments (NF) in blood serum in SMA patients at the presymptomatic stage before initiation of gene therapy and after 6, 12, 18, and 24 months after its implementation.Results. In our study, SMA patients at the presymptomatic stage, both before and after gene therapy, had motor development in accordance with age norms and did not significantly differ from children without neurological pathology. A comparative analysis of the electroneuromyographic parameters in SMA children and a group of healthy children revealed no statistically significant differences in patients at the presymptomatic stage of SMA on the background of gene therapy. A comparative analysis of the levels of light and heavy NF chains in the blood serum in SMA patients at the presymptomatic stage before gene therapy and 76 neurologically healthy children obtained in a recent study showed the level of light NF chains in SMA to be significantly higher (p < 0.001) — Me — 6.00, Q1; Q3 = 6.00; 31.43 pg/ml and Me — 4.00, Q1; Q3 = 2.50; 9.57 pg/ml, respectively. At the same time, the level of heavy NF chains did not significantly differ when comparing SMA patients at the presymptomatic stage before gene therapy with healthy peers. The use of onasemnogen abeparvovec in SMA patients at the presymptomatic stage led to a statistically significant decrease in the level of light chains NF in the blood serum. The maximum decrease in NF was observed 3–6 months after the gene therapy.Conclusion. Carrying out gene therapy using the onasemnogen abeparvovek in SMA patients at the presymptomatic stage made it possible to prevent the development of symptoms of the disease and achieve the main stages of motor development milestones according to WHO criteria.Compliance with ethical standards. Permission to conduct this study was obtained from the local ethics committee of the National Medical Research Center for Children’s Health (Minutes of the Local ethics committee, meeting No. 10 dated 10/06/2022).Contribution:Kuzenkova L.M., Kurenkov A.L., Uvakina E.V., Fisenko D.A. — concept and design of research, writing, editing;Chernikov V.V. — statistical data processing, editing.All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.Funding. The study had no sponsorship.Conflict of interest. The authors declare no conflict of interest.Received: November 6, 2024Accepted: December 1, 2024Published: January 31, 2025


  • Open Access

    Trend in blood serum levels of light and heavy chains of neurofilaments in infants with spinal muscular atrophy against background of the use of gene therapy

    by Дарья Андреевна Фисенко, Людмила Михайловна Кузенкова, Алексей Львович Куренков, Елена Леонидовна Семикина, Евгения Владимировна Увакина, Владислав Владимирович Черников, Ольга Владимировна Курбатова, Tatiana M. Komyagina, Matvei V. Konyashin, София Георгиевна Попович, et al.

    Introduction. Determination of neurofilaments (NF) levels in blood serum and CSF in children with spinal muscular atrophy (SMA) may be a promising biomarker of the severity and course of the disease, as well as a way of assessing the effectiveness of pathogenetic therapy. The aim of the study was to determine the blood serum NF levels of in 0–24 months infants with SMA type I at the presymptomatic stage of the disease before and after gene therapy with onasemnogene abeparvovec (OA). Materials and methods. The study included one hundred fifty five 0–24 months infants including 76 neurologically healthy children (group II), as well as 79 patients with SMA from group I (subgroup Ia — 44 infants with SMA type I, Ib — 35 infants at the presymptomatic stage of the disease) with a diagnosis of SMA. The majority of infants with type I SMA (subgroup Ia) had 2 copies of the SMN2 gene (n = 43; 97.7%), while infants from subgroup Ib (asymptomatic patients) had 3 copies (n = 31; 88.6%). Results. The values of NF light and heavy chains in infants from group I were obtained before and after 3–6, 7–12, and 13–24 months after gene therapy with OA. The NF light chains level in the Ia subgroup before treatment was significantly higher than in the Ib subgroup (p < 0.001) and higher than in the control group (p < 0.001). The serum level of NF heavy chains in the Ia subgroup before treatment was also significantly higher than in the control group. In the Ia subgroup, there was a significant decrease (p < 0.01) in serum NF light chains 3–6 months after gene therapy (Me [Q1; Q3] — 22.97 [6.00; 48.54]) compared with the same indices before treatment (6.0 [5.92; 7.78]). Subsequently, after 7–12 months (6.15 [5.15; 7.30]) and 13–24 months (6.0 [5.7; 6.6]), stabilization of Me values was noted with a decrease in interquartile ranges. In the Ib subgroup, there was also a significant decrease (p < 0.01) in serum NF light chains levels 3–6 months after OA gene therapy (6.0 [6.00; 7.25]) compared with these indices before treatment (6.0 [6.00; 31.43]). Conclusion. Determination of the blood serum NF light and heavy chains levels in SMA patient before and after gene therapy can be regarded as a marker of the severity of the disease and the effectiveness of treatment.


  • Open Access

    The efficacy of gene therapy with onasemnogene abeparvovec in spinal muscular atrophy in young patients

    by Дарья Андреевна Фисенко, Алексей Львович Куренков, Людмила Михайловна Кузенкова, Владислав Владимирович Черников, Евгения Владимировна Увакина, София Георгиевна Попович, Бэлла Ибрагимовна Бурсагова, Луизат Муслимовна Абдуллаева, Юлия Александровна Курова, Надежда Сергеевна Адалимова, et al.

    Introduction. The advent of pathogenetic therapy has significantly changed the prognosis for spinal muscular atrophy (SMA). However, our knowledge of the pathogenetic methods of treating SMA is mostly based on the results of clinical trials, which are largely limited due to the narrow criteria for selecting patients and the short duration of the following-up. Objective. To evaluate the efficacy of onasemnogene abeparvovec gene therapy in patients with SMA type I with clinical manifestations of the disease and in children at the presymptomatic stage of the disease in real clinical practice. Materials and methods. The study included seventy nine SMA children including 42 boys (53.2%). The diagnosis was verified during DNA diagnostics. The children were divided into two subgroups, depending on whether they had symptoms of SMA at the time of inclusion in the study or not. 44 children had SMA type I with the onset of clinical symptoms before the age of 6 months of life. 35 children were at the presymptomatic stage of the disease. All patients received gene therapy with onasemnogene abeparvovec, the average age at the moment of conduction of therapy was 2.90 ± 1.74 months (95% CI: 2.51–3.29 months), min — 1.00 month, max — 7.00 months. A comprehensive assessment of clinical parameters (stages of motor development milestones according to WHO recommendations, HINE-2 and CHOP-INTEND scores) was carried out before the initiation of gene therapy and 6, 12, 18 and 24 months after its implementation. Results. Children with SMA type I showed favour trend in motor development milestones after gene therapy. By the end of the second year of the follow-up, 88.6% of patients held their head erect and rolled from back to sides; 60.5% could sit without support, but only 10.3% were able to achieve all motor skills, but none of these children achieved them in accordance with WHO criteria. The HINE-2 score increased from Me of 2.0 (1.00–2.25) points at the initiation of therapy to Me of 20.00 (16.50-24.50) points by the end of the follow-up period. Only two children (4.5%) of this subgroup reached the maximum score of 26 points. The CHOP-INTEND score increased from Me of 30.0 (22.00–37.25) points before starting treatment to Me of 60.0 (58.0-64.0) points by 24 months of follow-up. Only 11.4% of patients with SMA type I reached the maximum score of 64 points. The majority of the presymptomatic patients in our study achieved all motor development milestones according to WHO criteria according to their age on the background of gene therapy. All children from this subgroup who were under sufficient supervision and reached the age of walking alone (23 children) had a maximum HINE-2 score of 26 points by the age of 18 months. All children from this subgroup reached the maximum CHOP-INTEND score of 64 points by the age of 6 months. Conclusion. The usage of onasemnogene abeparvovec in children with SMA type I both significantly modifies the course of the disease and improves outcomes compared with the natural history of SMA course with early onset, and the usage of gene therapy in most of the presymptomatic patients leads to the achievement of motor development milestones in accordance with WHO criteria.


  • Open Access

    Trend in parameters of motor nerve conduction against the background of gene therapy in early age patients with spinal muscular atrophy

    by Дарья Андреевна Фисенко, Алексей Львович Куренков, Людмила Михайловна Кузенкова, Владислав Владимирович Черников, Евгения Владимировна Увакина, София Георгиевна Попович, Бэлла Ибрагимовна Бурсагова, Тамара Николаевна Белоусова, Natalya Yu. Kniazeva, Максим Юрьевич Новиков, et al.

    Introduction. In children with spinal muscular atrophy (SMA), reliable indicators (biomarkers) are needed to predict the disease, which could reflect the underlying process of the disease. It is believed that the parameters of motor nerve conduction studies (MNCV) (amplitude and area of the compound muscle action potential (CMAP), the motor unit number estimation) may correlate with the degree of denervation in SMA and with the severity of motor disorders. The purpose of the study. To detect the trend in MNCV parameters in SMA type I patients with clinical manifestations of the disease and children at the presymptomatic stage of the disease, against the background of treatment with onasemnogen abeparvovek. Materials and methods. The study included sixty eight SMA children, including 42 boys (53.2%). All children received gene therapy with the onasemnogen abeparvovek. 33 children were treated at the presymptomatic stage (age at the time of treatment was 2.12 ± 0.91 years (95% CI 1.80–2.45), min — 1.00, max — 5.00). In 35 SMA type I children, treatment started when clinical symptoms of the disease were already present (age at the time of treatment was 3.40 ± 1.85 years (95% CI 3.10–4.25), min — 1.00, max — 7.00). All children included in this study underwent MNCV before the start of therapy and for the next 2 years. The amplitude of the negative peak of the CMAP from the abductor digiti minimi muscle during stimulation of the ulnar nerve and nerve conduction velocity (NCV) along the distal part of the ulnar nerve were determined. Due to the fact that the values of most of the MNCV parameters did not obey the normal distribution, they were described using the values of the median (Me) and the lower and upper quartiles (Q1–Q3), minimum (min) and maximum (max). Results. In the cohort of presymptomatic patients, the CMAP and NCV parameters did not significantly differ from the normative data before the start of therapy, and against the background of treatment with onasemnogen abeparvovek, an increase in the CMAP and NCV amplitude of the was noted with increasing age in patients. The amplitude of the CMAP and NCV before treatment were 5.00 mV (4.30–5.30), min — 1.40, max — 8.00 and 33.60 m/s (32.40–38.10), min — 27.40, max — 48.90, and at the age of 13 to 24 months — 6.25 mV (5.20–6.85), min — 4.70, max — 7.80 and 55.20 m/s (52.80–57.60), min — 49.10, max — 60.30, respectively. All SMA type I patients showed a significant decrease in the amplitude of the M-response both before therapy and during 2-year follow-up after the start of treatment. The amplitude of the CMAP and NCV before treatment were 0.28 mV (0.13–0.65), min — 0.05, max — 2.20 and 31.90 m/s (27.50–35.90), min — 22.30, max — 52.00, and at the age of 13 to 24 months — 0.70 mV (0.46–1.15), min — 0.17, max — 4.60 and 48.40 m/s (43.95–50.98), min — 38.90, max — 56.10, respectively. Conclusion. When comparing the MNCV parameters in presymptomatic with SMA type I patients, significant differences were shown, which were manifested in symptomatic patients with a low amplitude of the CMAP and reduced values of NCV both before therapy and during 2-year follow-up after treatment with onasemnogen abeparvovek. Thus, conducting MNCV in children with SMA is an easily feasible study, and evaluating the amplitude of the CMAP makes it possible to reliably, albeit indirectly, verify degeneration of spinal cord motor neurons in symptomatic patients against the background of pathogenetic treatment.

  • Open Access

    Normative parameters of motor nerve conduction studies in infants

    by Дарья Андреевна Фисенко, Алексей Л. Куренков, Lyudmila M. Kuzenkova, Vladislav V. Chernikov, Eugeniya V. Uvakina, Bella I. Bursagova, Sophia G. Popovich

    Introduction. Electromyography (EMG) is a modern method of instrumental neurophysiological diagnostics, which includes two main techniques as nerve conduction studies and needle EMG. Parameters of motor nerve conduction studies have been used in a number of clinical studies to evaluate the effectiveness of treatment in children with spinal muscular atrophy (SMA) during the use of pathogenetic therapy (nusinersen). Now, in our country there are no verified normative parameters of motor nerve conduction studies in infants. It is also worth saying that neonatal screening for identifying SMA patients started in 2023 in our country, and currently gene therapy for this disease is increasingly used, so improving methods for instrumental assessment of the dynamics of the condition during treatment, including using EMG, is relevant. Objective: to determine the normative parameters of motor nerve conduction studies in 1–6 months, 7–12 months, and 13–24 months infants without neurological pathology. Materials and methods: The motor nerve conduction studies were carried out using a 2-channel electromyograph Neuro-MVP-Micro (Russia) with electrical stimulation of the ulnar nerve and registration of the compound muscle action potential (CMAP) from the abductor digiti minimi muscle. This made it possible to determine the main parameters of the negative peak of the CMAP — distal latency, amplitude and area, and calculate the motor nerve conduction velocity (MNCV) along the distal part of the ulnar nerve. The obtained data for each parameter were subject to normal distribution and presented in the form of mean and standard deviation (M±SD), minimum and maximum values (min – max). Results: In the age range of 1–6 months, the amplitude of the CMAP (mV) was 5.0±1.0 (3.0–8.0); CMAP area (ms∙mV) — 9.1 ± 2.1 (5.5–12.9); distal latency (ms) — 2.2 ± 0.2 (1.6–2.5), MNCV (m/s) — 37.5 ± 5.4 (27.5–48.9). In the age range of 7–12 months, the amplitude of the CMAP (mV) was 6.2 ± 1.3 (3.8-9.3); CMAP area (ms∙mV) — 11.7 ± 3.0 (6.5–18.6); distal latency (ms) — 2.0 ± 0.2 (1.4–2.4), MNCV (m/s) – 48.4 ± 4.1 (42.1–55.2). In the age range of 13-24 months, the amplitude of the CMAP (mV) was 6.4 ± 0.6 (5.0-7.3); CMAP area (ms∙mV) — 13.3 ± 2.8 (9.8–18.2); distal latency (ms) — 2.2 ± 0.2 (1.8–2.5), MNCV (m/s) – 52.6 ± 3.8 (41.8–57.3). Conclusion. For the first time, normative parameters of motor nerve conduction studies were obtained in 1–6, 7–12, and 13–24 months infants without neurological pathology. This will make it possible to objectify neurophysiological parameters in neuromuscular diseases in infants.


  • Open Access

    Neurofilaments as a biomarker of spinal muscular atrophy: review

    by Дарья Андреевна Фисенко, Lyudmila M. Kuzenkova, Алексей Л. Куренков, Eugeniya V. Uvakina, Sophia G. Popovich

    Spinal muscular atrophy (SMA) is an autosomal recessive, disabling neuromuscular disease characterized by the death of motor neurons in the spinal cord, giving rise in the development both of muscle weakness and, subsequently, flaccid tetraparesis, swallowing and breathing disorders. There are 4 types of SMA, depending on the age of manifestation, the most severe is type I (not counting type 0 — prenatal type). Modern diagnosis of SMA includes a molecular genetic study looking for mutations in the SMN1 gene and determining the copy number of the SMN2 gene. Instrumental and biochemical methods for evaluating the effectiveness of therapy for spinal muscular atrophy are currently under study. Neurofilament proteins have been investigated as potential biomarkers for several diseases characterized by axonal damage and degeneration. In clinical studies, there are isolated data on the use of blood neurofilaments as markers of SMA. This review considers the literature data of foreign authors and clinical studies of neurofilaments as perspective biomarkers of SMA, both heavy and light chains.


  • Open Access

    Safety profile of onasemnogene abeparvovec in children with spinal muscular atrophy

    by Lyudmila M. Kuzenkova, Evgeniya V. Uvakina, Sofiya G. Popovich, Tatyana V. Podkletnova, Aleksandra A. Nezhelskaya, Luizat M. Abdullaeva, Darya A. Fisenko, Alena V. Naidenko

    Goal. To evaluate the safety profile of onasemnogene abeparvovec (Zolgensma®) gene therapy in children with spinal muscular atrophy (SMA) in real clinical practice. Materials and methods. The study included 30 SMA children who underwent gene replacement therapy with onasemnogene abeparvovec (Zolgensma®) from December 2020 to December 2021 at the Center for Pediatric Psychoneurology. All children had a diagnosis of SMA confirmed by molecular genetic methods, with no more than 3 copies of the SMN2 gene and the absence of antibodies to the adeno-associated virus serotype 9. The safety profile was assessed by monitoring the clinical and laboratory data of the patients after administration of onasemnogene abeparvovec. Clinical events included all changes in the child’s condition that could be associated with the administration of the drug (hyperthermia, decreased appetite, nausea, vomiting, stool disorders). Laboratory assessment included monitoring of complete blood count, biochemical blood tests, blood coagulation indices. The degree of laboratory changes was estimated according to common terminology criteria for adverse events (CTCAE version 5.0). Results. The safety profile of the drug Zolgensma® was studied in 30 children aged from 3 to 39 months, with a weight of 5.2 kg to 14.2 kg. Twenty-eight (93.3%) children had at least one clinical event associated with the administration of the drug. Hyperthermia was observed in 24 (80%) children, nausea and vomiting in 18 (60%) children, decreased appetite in 20 (66.7%) children, stool changes in 4 (13.3%) children. Monitoring of laboratory indices revealed thrombocytopenia and monocytosis in twenty-two (73.3%) children and neutropenia in twelve (40%) children in the general blood test. An increase in the level of transaminases was noted in all children, the CTCAE grade 1 was detected in fifteen (50%) children, the CTCAE grade 2 in 7 (23.3%) children, CTCAE grade 3 in 6 (20%) children, CTCAE grade 4 in 2 (6.7%) children. Children with CTCAE grade 3 required correction of the prednisone dose up 2 mg/kg per day for 2-4 weeks. Two children with CTCAE grade 4 required pulse therapy with methylprednisolone at a dose of 30 mg/kg per day. Regardless of the level of transaminases, no change in the level of total and direct bilirubin was observed in any case. A decrease in prothrombin time was observed in 14 (46.6%) children. An increase in the level of troponin I was detected in four (13.3%) children. In all cases of serious adverse events, according to laboratory indices, the clinical condition of the children remained stable. The average duration of prednisone intake was 17.8 ± 6.6 weeks. Conclusion. The safety profile of the drug onasemnogene abeparvovec (Zolgensma®) in real clinical practice in children with SMA is presented.


  • Changes of the spasticity patterns in children with cerebral palsy GMFCS III at the age of 2 to 12 years

    by А. Л. Куренков, Л. М. Кузенкова, Д. А. Фисенко, O.A. Klochkova, Б. И. Бурсагова, V.V. Chernikov

    Spastic muscles in the pathological motor patterns may change at different ages that leads to the changes in anti-spastic treatment. To study the specific patterns of spasticity in CP patients with level III according to the Gross Motor Function Classification System (GMFCS) in different age periods. A retrospective analysis of injection protocols of Abobotulinum toxin A for 99 patients with bilateral spastic CP GMFCS III at the age of 2 to 12 years was performed. Spasticity patterns were evaluated according to the frequency of target muscle selection for the botulinum toxin A (Abobotulinum toxin A) injections. The equinus foot deformity (89.7%, 95%CI 72.8-97.2) and its combination with internal hip rotation (79.3%, 95% CI 61.3-90.5) and/or hip adduction (65.5%, 95% CI 47.3-80.2) were the main lower extremity spasticity pattern for the patients aged 2 to 4 years. Between 4 and 6 years, there was the decrease in injections to the gastrocnemius muscle (75%, 95% CI 52.8-89.2), and less to the m. gracilis (70%, 95% CI 47.9-85.7) and hip adductors (55% 95 CI 34.2-74.2). In the 6-12 year old patients, the predominant spasticity patterns were internal hip rotation (80%, 95% CI 66.8-88.9), adduction (54%, 95% CI 40.4-67.0) and knee flexion (66%, 95% CI 52.1-77.6). The leading upper extremity patterns at all observed ages were forearm pronation (70.7%, 95% CI 61.1-78.8) and elbow flexion (47.5%, 95% CI 37.9-57.2). The frequency of injections to these muscles slightly decreased in elder groups. CP GMFCS III patients demonstrate age-related changes of the spasticity patterns both in lower and upper extremities. These changes and typical spastic muscles should be taken into account during the rehabilitation and botulinum toxin treatment planning, as well as in the detection and prevention of the orthopaedic complications.